banner
You are not using a standards compliant browser. Because of this you may notice minor glitches in the rendering of this page. Please upgrade to a compliant browser for optimal viewing:
Firefox
Internet Explorer 7
Safari (Mac and PC)
Press Release
Study links long-term use of osteoporosis drugs to unusual fractures
Wednesday, February 23, 2011


Osteoperosis fractures

Women who take commonly prescribed drugs for osteoporosis known as bisphosphonates for five years or more may be at higher risk of certain kinds of fractures of their thigh bone, a new study has found.

However, the drugs do prevent hip fractures. And, since the overall risk of thigh bone fractures caused by the drugs is low, women at high risk for hip and other osteoporosis-related fractures should not stop taking bisphosphonates, according to researchers at St. Michael's Hospital and the Institute for Clinical Evaluative Sciences.

The study was published today in the Journal of the American Medical Association (JAMA).

Typical hip fractures caused by osteoporosis occur in the upper part of the femur close to the hip joint and are an important cause of disability, need for long-term care and even death in the elderly. The risk of these kinds of fractures is reduced by bisphosphonate treatment, which was confirmed by this study.

But the study found that less common fractures lower down from the hip and closer to the middle of the femur –sometimes called "atypical" or "unusual" fractures -- occurred more than 2.5 times as often in women who had taken bisphosphonates for more than five years than short-term users of the drug..

"Prolonged use of bisphosphonates is associated with rare and unusual fractures of the femur," said the lead author, Laura Park-Wyllie, a pharmaceutical safety and outcomes researcher at St. Michael's. "But the proven benefit of these drugs for the much more common fractures of osteoporosis usually outweighs the harm, especially in the initial years of treatment for osteoporosis. Women with osteoporosis, at high risk for osteoporotic fractures, should not stop taking bisphosphonate therapy because of the small risk of these thigh fractures."

Park-Wyllie said the study was prompted by an increasing number of reports of thigh bone fractures among older women who have taken the drugs sold as Fosamax, Actonel or Didrocal for five years or more and by conflicting findings from small, observational studies.

The St. Michael's-ICES study is the largest assessment of the issue to date. The researchers identified 205,466 women over age 68 who had been prescribed bisphosphonates between 2002 and 2008.

Of those, 716 women (0.35 per cent) had a fracture of the femur. These women were compared to other women of similar ages who had also been prescribed the drugs but who did not have femur fractures.

"Our study estimated that the risk of fractures to the femur was 0.13 per cent for women entering their sixth year on the drug – or just over one in 1,000," Park-Wyllie said. "Use of bisphosphonates for less than five years was not associated with a significant risk of thigh fractures."

About 50 per cent of women over 50 will suffer an osteoporosis-related fracture. The most common involve the wrist and the spine, but hip fractures can have some of the most severe consequences, with one in five of those women expected to die within 12 months.

 

###

St. Michael's Hospital: http://www.stmichaelshospital.com/



Thanks to St. Michael's Hospital for this article.

This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.



This press release has been viewed 630 time(s).

Comments
No comments recorded.
Add Comment?
Comments are closed 2 weeks after initial post.
Friends